THE TAPE

CryoPort, Inc. Common Stock

$19.80▼ −0.45%
Last close
Relative strength
96RS
of 99, against every stock▲ +5 on the month
Powering up
Developing
+33.9%
six months against Pharmaceutical Preparations
52-week range
−9.1%
from the high
$7.61$21.78
Setup
blue skyplayed out
+15.1%
against the pivot at $17.20
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +14% on a year ago
11/16 O 19.63 H 20.06 L 19.49 Vol 626.2K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS96
vs pivot+15.12%
Tightening1.18×
Dry-up0.85×
Up/down vol0.07
From high9%
played out7 of 9checks
Previous breakout stopped out ▼ −9.22% in Aug
Powering up
Support and resistance
Support below
$18.00
-9.1% · tested 3× · last 26 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 4.0 weeks and fell 15% from its ceiling at its deepest. The pivot is $17.20, and the stock closed 15.1% above that pivot. Its relative strength rating is 96.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+12.6%
Three months against its industry
+51.6%
Six months against its industry
+33.9%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 16.4% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$192.4M
+13.5% year on year
Operating margin
-20.0%
gross 46.9%
Net margin
-21.5%
Free cash flow
$-18.8M
-1.9% of market cap
Price to sales
5.21×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Cash flow is the weak point of the quarter.
Revenue
$50.2M
+2.6% QoQ · +13.5% YoY
Gross margin
47.5%
+0.9 pts QoQ
Net income
−$10.9M
Loss
Free cash flow
−$40.0K
Burning

What the numbers say

  • Revenue +13.5% year over year, +2.6% on the quarter
  • Gross margin 47.5%, +0.9 points on the quarter
  • Weak: Net loss $11M, wider than $8M last quarter
  • Weak: Burning cash: operating cash flow $5M, free cash flow -$40K, better than -$8M last quarter
  • Weak: Growth externally funded: capex $5M against operating cash flow $5M
  • Good: Net cash $279M · cash $279M
Revenue by quarter
Free cash flow
Net income
shares +1.1% in a year · net cash $279.2M

What is not obvious

  • Margin quality: depreciation and amortisation $6M is 13% of revenue; gross margin 47.5% reads 34.6% if it is charged there
  • Weak: Interest $517K a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $11M, wider than $8M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Pulled back while its group leadsTape · 2026-11-14
3 lower closes in a leading group, 50d held, at 19.89
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
New 52-week highTape · 2026-11-10
2.4x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
GappedTape · 2026-11-10
+7.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
New 52-week highTape · 2026-11-07
2.7x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-07
above 20d & 50d on 2.7x volume at 19.10
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-07
+19.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-07
+19.0% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Unusual volumeTape · 2026-11-07
3.1 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 12 days agoCencora (COR) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research · 13 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
0
Sold on the open market
7
$5,754,621 total

Sold: Sawicki Mark W, HANCOCK DANIEL M, SHELTON JERRELL, ZECCHINI EDWARD J, Mandalam Ramkumar, STEFANOVICH ROBERT.

Not counted above: 9 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-10 Sawicki Mark W · Chief Scientific Officersell10,000$199,261
2026-11-09 HANCOCK DANIEL M · Directoroption exercise30,000$291,900
2026-11-09 HANCOCK DANIEL M · Directoroption exercise23,830$301,450
2026-11-09 HANCOCK DANIEL M · Directoroption exercise20,549$143,843
2026-11-09 HANCOCK DANIEL M · Directorsell74,379$1,502,976
2026-08-11 SHELTON JERRELL · President, CEO, Directorsell28,800$429,385
2026-06-11 ZECCHINI EDWARD J · Chief Digital and Tech Officeroption exercise33,600$161,280
2026-06-11 ZECCHINI EDWARD J · Chief Digital and Tech Officersell33,600$486,239

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$20.37
The pole · over 4 sessions+28.1%
Through to the apex38%
Touches · swing points the lines are drawn through3 up · 3 down
Length0.6 weeks
What lines up

7 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy1
Buy7
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray
4w · 15%

The most recent of 5 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
CryoPort, Inc. Common Stock (CYRX) — The Tape